Medtronic Announces Upcoming Data Presentations at the Advanced Technologies and Treatments for Diabetes 11th International C...
February 13 2018 - 9:00AM
Medtronic Will
Host an Exclusive Symposium on Thursday, February 15
VIENNA - February 13, 2018 -
Medtronic plc (NYSE:MDT), the global leader in medical technology,
today announced its schedule of notable sessions that will be
presented at the Advanced Technologies & Treatments for
Diabetes (ATTD) 11th
International Conference in Vienna, Austria, from February 14-17. A
significant portion of the scientific data being presented focuses
on the company's insulin pump systems, including new data on the
benefits of the latest SmartGuard(TM) technology that drives the
MiniMed(TM) 670G system1 in
children with type 1 diabetes. Medtronic will also host an
exclusive symposium titled "Using Technology to Increase Time in
Range: The New Goal for Glycemic Control" on Thursday, February 15,
from 10:30-12:00 CET.
Scientific Presentations
-
"Exploratory Analysis for Selected Patients with
DP During the MiniMed 670G HCL Pivotal Trial" - e-poster
presentation by Dr. Richard Bergenstal
-
"Evaluation of the MiniMed 670G System PLGM
Feature in Children" - oral presentation by Dr. Gregory
Forlenza
-
"Glycemic Outcomes During MiniMed 670G System
Use in Children with T1D" - oral presentation by Dr. Bruce
Buckingham
-
"Real-world Use of the MiniMed 670G HCL System"
- oral presentation by Pratik Agrawal
-
"Study Design of Randomized, Adaptive Trial in
Adult and Pediatric Patients with T1D Using MiniMed 670G Versus
Control (CSII, MDI or SAP)" - e-poster presentation by Dr. John
Shin
-
"CareLink Analysis for Real-world Non-Adjunctive
CGM Insights" - e-poster presentation by Ashley Sullivan
-
"Real-world Assessment of Former MDI Patients'
Experience on the Medtronic MiniMed 670G HCL System" - e-poster
presentation by John Mueckler
-
"Real-world Assessment of the Patients'
Experience on the Medtronic MiniMed 670G HCL System" - e-poster
presentation by John Mueckler
-
"MiniMed 670G Pivotal Trial: Timing of Meal
Bolus Plays a Critical Role in Postprandial Glucose Control" -
e-poster presentation by Dr. Anirban Roy
-
"MiniMed 670G System Adaptation Effectiveness -
Results from the Pivotal Trial" - oral presentation by Dr. Benyamin
Grosman
-
"Avoidance of Glucose Excursions by the Guardian
Connect CGM System-Real-world Data" - e-poster presentation by
Dr. Chantal McMahon
Workshops
-
Beyond HbA1c: Professional CGM Enhances
Therapeutic Choice, Patient Empowerment, Shared Decision-Making and
Reduces Healthcare Costs - presentation by Dr. Robert Vigersky and
Prof. Rogerio Ribeiro on Wednesday, February 14, from 14:30-16:00
in Hall L3
-
MiniMed(TM) 640G System: Maximizing the Power of
SmartGuard Technology to Increase Time in Range - presentation by
Prof. Emanuele Bosi and Dr. Robert Vigersky on Wednesday, February
14, from 16:15-17:45 in Hall L3
-
Improving Patients' Experience with Insulin
Infusion and Injection Port Solutions: A Hands-On Session to
Discover the Use of MiniMed(TM) Mio(TM) Advance Infusion Set and
i-Port Advance(TM) Injection Port to Benefit Your Patients -
presentation by Dr. Carine de Beaufort, Geraldine Gallen and Emma
Day on Wednesday, February 14, from 16:15-17:45 in Hall N
-
Guardian(TM) Connect CGM: Why Prediction,
Education and Data Interpretation are Key for Sustained Better
Outcomes - presentation by Prof. Ohad Cohen, Dr. Andrea Scaramuzza
and Laurent Barsin on Thursday, February 15, from 13:00-14:30 in
Hall L3
-
HbA1c Reduction: Impact of CSII in Type 2
Diabetes Management; Meta-Analysis Use and Abuse in Diabetes
Technology - presentation by Prof. John Pickup and Prof. Ohad Cohen
on Friday, February 16, from 9:00-10:00 in Hall L3
Symposium
Medtronic will host an exclusive symposium titled
"Using Technology to Increase Time in Range: The New Goal for
Glycemic Control" on Thursday, February 15, from 10:30-12:00 in
Hall A Level 2. Chaired by Prof. Tadej Battelino, the symposium
will feature the following presentations:
-
Time in Range: The Emerging Metric for Glycemic
Control - by Dr. Patrick Choudhary
-
Predictive Algorithms to Enhance Time in Range -
by Prof. Ohad Cohen
-
Hybrid Closed Loop Achievements in Increasing
Time in Range - by Dr. Francine R. Kaufman
For more information about Medtronic products,
attendees are encouraged to visit the Medtronic booth 01.
About the Diabetes Group at
Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global
community to change the way people manage diabetes. The company
aims to transform diabetes care by expanding access, integrating
care and improving outcomes, so people living with diabetes can
enjoy greater freedom and better health.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered
in Dublin, Ireland, is among the world's largest medical
technology, services and solutions companies - alleviating pain,
restoring health and extending life for millions of people around
the world. Medtronic employs more than 84,000 people worldwide,
serving physicians, hospitals and patients in approximately 160
countries. The company is focused on collaborating with
stakeholders around the world to take healthcare Further,
Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
1 The
MiniMed 670G system is currently not CE marked. Medtronic is
currently working alongside regulatory bodies outside of the U.S.
to make the MiniMed 670G system commercially available across the
world. Approval timelines are subject to the regulatory process of
individual countries and regions.
Contacts:
Pamela Reese
Public Relations
+1-818-576-3398
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024